Label-free quantitative proteomics reveals differentially expressed proteins in high risk childhood acute lymphoblastic leukemia

Xu, Gang; Li, Zhijie; Wang, Lili; Chen, Fang; Chi, Zuofei; Gu, Min; li, Shuang; Wu, Di; Jiang, Miao; Zhang, Yi; Hao, Liangchun; Yang, Fan

doi:10.1016/j.jprot.2016.08.014

Cited by 15 publications

(12 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another example of the use of MS in the identification of new molecules for diagnosis and risk stratification in BCP-ALL is the study carried out by Xu et al [54]. Authors analyzed by liquid chromatography-…”

Section: Mass Spectrometry In the Establishment Of The Molecular Basis Of Leukemogenesis And In Discovery Of Molecular Markers For Bcp-almentioning

confidence: 99%

Proteomic tools and new insights for the study of B-cell precursor acute lymphoblastic leukemia

Citalán-Madrid

Cabral-Pacheco

Martínez-de-Villarreal

et al. 2019

Hematology

View full text Add to dashboard Cite

B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a hematological malignancy of immature B-cell precursors, affecting children more often than adults. The etiology of BCP-ALL is still unknown, but environmental factors, sex, race or ethnicity, and genomic alterations influence the development of the disease. Tools based on protein detection, such as flow cytometry, mass spectrometry, mass cytometry and reverse phase protein array, represent an opportunity to investigate BCP-ALL pathogenesis and to identify new biomarkers of disease. This review aims to document the recent advancements with respect to applications of proteomic technologies to study mechanisms of leukemogenesis, how this information could be used in the discovery of biological targets, and finally we describe the challenges of application of proteomic tools for the approach of BCP-ALL.

show abstract

Section: Mass Spectrometry In the Establishment Of The Molecular Basis Of Leukemogenesis And In Discovery Of Molecular Markers For Bcp-almentioning

confidence: 99%

Proteomic tools and new insights for the study of B-cell precursor acute lymphoblastic leukemia

Citalán-Madrid

Cabral-Pacheco

Martínez-de-Villarreal

et al. 2019

Hematology

View full text Add to dashboard Cite

show abstract

“…Advances in chromatographic separation of enzymatically cleaved peptides and their subsequent detection by tandem mass spectrometry have made it possible to identify thousands of proteins within a single-shot LC-MS/MS experiment [ 1 , 2 ]. Global comparative proteome analyses of healthy and diseased tissues can provide valuable information on the specific pathological mechanism of a given disease [ 3 , 4 , 5 , 6 , 7 ]. This knowledge can support the development of targeted therapies [ 8 ] or diagnostic tests based on identified biomarkers [ 3 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Study on Tissue Homogenization Buffer Composition for Brain Mass Spectrometry-Based Proteomics

Karpiński

Elguera²,

Sanner³

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Mass spectrometry-based proteomics aims to study the proteome both qualitatively and quantitatively. A key step in proteomic analysis is sample preparation, which is crucial for reliable results. We investigated the effect of the composition of the homogenization buffer used to extract proteins from brain tissue on the yield of protein extraction and the number and type of extracted proteins. Three different types of buffers were compared—detergent-based buffer (DB), chaotropic agent-based buffer (CAB) and buffer without detergent and chaotropic agent (DFB). Based on label-free quantitative protein analysis, detergent buffer was identified as the most suitable for global proteomic profiling of brain tissue. It allows the most efficient extraction of membrane proteins, synaptic and synaptic membrane proteins along with ribosomal, mitochondrial and myelin sheath proteins, which are of particular interest in the field of neurodegenerative disorders research.

show abstract

“…The B‐ALL etiology is not clear 3 ; however, the malignant transformation occurs in several stages of differentiation. Additionally, this form of leukemia showed several characteristics, including genomic rearrangements, 3 several mutations, 4 copy number variations, 5 transcriptomic alterations, 6 and leukemia‐associated proteomic profiles 7 …”

Section: Introductionmentioning

confidence: 99%

“…Additionally, this form of leukemia showed several characteristics, including genomic rearrangements, 3 several mutations, 4 copy number variations, 5 transcriptomic alterations, 6 and leukemia-associated proteomic profiles. 7 B-ALL is predicted to have a good outcome; however, in developing countries, malnutrition and the time before diagnosis have been associated with poor prognosis. 8,9 In fact, the B-ALL diagnosis options are focused on evaluating cellular morphology, and immunophenotyping is performed by flow cytometry.…”

Section: Introductionmentioning

confidence: 99%

v‐myb avian myeloblastosis viral oncogene homolog expression is a potential molecular diagnostic marker for B‐cell acute lymphoblastic leukemia

Caballero-Palacios¹,

Villegas-Ruíz²,

Ramírez-Chiquito³

et al. 2020

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Background B‐cell acute lymphoblastic leukemia (B‐ALL) is the most commonly diagnosed childhood malignancy worldwide and is especially common in Mexico. Additionally, the number of cases has increased in recent years. Thus, it is very important to develop molecular strategies to diagnose leukemia. The aim of this study was to investigate MYB expression and to determine its impact on the diagnosis of B‐ALL. Methods We analyzed the B‐ALL gene expression profile by microarray data mining. Bioinformatics analysis was performed to identify the genes that are overexpressed in leukemia. We determined that MYB was highly expressed in leukemia. Then, we validated MYB expression in 70 patients with B‐ALL and in 16 healthy controls (HCs) using qRT‐PCR. The results were statistically analyzed using the Kolmogorov‐Smirnov Z test, Mann‐Whitney U test, receiver operating characteristic curves, and the Youden index. Results The microarrays showed that MYB was overexpressed in B‐ALL patients with a fold change of 57.8728 and a P value of 2.56−195. MYB expression showed great variability among the patients analyzed. However, compared to the HCs, the B‐ALL patients had a P value < .0001, an area under the curve of 0.813, and a Youden index of 1.46, indicating the statistical significance. Conclusion MYB expression in B‐ALL cells could be a potential molecular marker for childhood leukemia.

show abstract

Label-free quantitative proteomics reveals differentially expressed proteins in high risk childhood acute lymphoblastic leukemia

Cited by 15 publications

References 53 publications

Proteomic tools and new insights for the study of B-cell precursor acute lymphoblastic leukemia

Proteomic tools and new insights for the study of B-cell precursor acute lymphoblastic leukemia

Study on Tissue Homogenization Buffer Composition for Brain Mass Spectrometry-Based Proteomics

v‐myb avian myeloblastosis viral oncogene homolog expression is a potential molecular diagnostic marker for B‐cell acute lymphoblastic leukemia

Contact Info

Product

Resources

About